Insulin icodec/semaglutide - Novo Nordisk
Alternative Names: Icosema; Insulin icodec/semaglutide; NN 1535; Semaglutide/insulin icodecLatest Information Update: 25 Jul 2024
At a glance
- Originator Novo Nordisk
- Class Antihyperglycaemics; Insulins; Pancreatic hormones
- Mechanism of Action Glucagon-like peptide-1 receptor agonists; Phosphokinase stimulants; Protein tyrosine kinase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Type 2 diabetes mellitus
Most Recent Events
- 25 Jul 2024 Novo Nordisk intends to submit a regulatory application to the European Medical Agency (EMA) for Type 2 diabetes mellitus in H2 2024 (SC)
- 23 Apr 2024 Novo Nordisk completes a phase-III clinical trial in Type 2 diabetes mellitus (In the elderly, In adults) in Finland, Norway, Croatia, Belgium, Australia, China, India, Japan, South Korea, Mexico, Russia, Serbia, South Africa, Taiwan, Turkey, Italy, Japan, Poland, Portugal, Puerto Rico, Romania and the USA (SC) (NCT05352815)
- 15 Feb 2024 Phase-III clinical trials in Type 2 diabetes mellitus (Adjunctive treatment, Treatment-experienced) in Turkey, South Africa, Poland, Japan, Italy, Greece, China, USA, India, Puerto Rico (SC) (EudraCT2022-502484-38-00) (NCT06269107)